– Demonstrated potential of FSHD-TUG and Emerald in-home assessments as accurate, low-burden clinical assessments of mobility for FSHD patients – – Company on track to report data from Phase 2b ReDUX4 ...
After a decade-long search for answers to her difficulties with walking and other physical activities, Joanne Dalessandro of North Barrington learned in late 2023 she had FSHD, or facioscapulohumeral ...
VANCOUVER, British Columbia & COLUMBUS, Ohio--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization committed to accelerating therapies for facioscapulohumeral muscular dystrophy (FSHD), ...
SAN DIEGO--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, today announced that Solve FSHD has provided one million dollars in support of n-Lorem’s efforts to fully understand the complex molecular ...
CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically ...
Facioscapulohumeral muscular dystrophy (Facio-face; scapulo-scapula or shoulder blade; humeral-arm muscles around the humerus) or FSHD is an inherited muscle disorder characterized by the progressive ...
Chip Wilson suffers from a rare form of muscular dystrophy and seeks scientific innovators to find a cure to help him and others. The world’s most successful entrepreneurs are often willing to share ...
Dyne Therapeutics, Inc. announced promising preclinical data for their therapeutic candidate, DYNE-302, which shows potential for functional improvement in facioscapulohumeral muscular dystrophy (FSHD ...
– DemonstratedWhole-Body MRI captures heterogeneity and provides key disease severity and progression information correlated with FSHD clinical endpoints – – Demonstrated potential of FSHD-TUG and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results